

Indian firm Lupin inks partnership with TB alliance to address drug resistance

06 September 2021 | News

For new therapy for highly drug-resistant TB



US headquartered TB Alliance has granted Indian pharma firm Lupin, a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen- bedaquiline (B), pretomanid (Pa) and linezolid (L).

Lupin intends to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.

Nilesh Gupta, Managing Director, Lupin added, “As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health.”

“Tuberculosis is one of humanity's oldest, deadliest, and most persistent diseases. Lupin is the largest supplier of first-line anti-TB drugs in the world, and we are excited to partner with TB Alliance to help bring new therapies for highly drug-resistant TB to reach individuals and countries where access to these medicines is so urgently needed,” said Naresh Gupta, President API Plus, Lupin.